Effects of the antiarrhythmic agent EGIS-7229 (S 21407) on calcium and potassium currents in canine ventricular cardiomyocytes

Naunyn-Schmiedeberg's Archives of Pharmacology

Volumn 363, Issue 6, 2001, Pages 604-611

  Magyar, János ^a   Bányász, Tamás ^a   Fülöp, László ^a   Szentandrássy, Norbert ^a   Körtvély, Ágnes ^a   Kovács, Anikó ^b   Szénási, Gábor ^b   Nánási, Péter P ^a  

^a UNIVERSITY OF DEBRECEN   (Hungary)

^b EGIS PHARMACEUTICALS LTD   (Hungary)

Author keywords

Antiarrhythmic drugs; Calcium current; Cardiac myocytes; Electrophysiology; Potassium currents

Indexed keywords

5 CHLORO 4 [3 [N [2 (3,4 DIMETHOXYPHENYL)ETHYL] N METHYLAMINO]PROPYLAMINO] 3(2H) PYRIDAZINONE; 5 CHLORO 4 [N (3,4 DIMETHOXYPHENYLETHYL)AMINOPROPYLAMINO] 3(2H) PYRIDAZINONE FUMARATE; ANTIARRHYTHMIC AGENT; UNCLASSIFIED DRUG;

ANIMAL CELL; ARTICLE; CALCIUM CURRENT; CONTROLLED STUDY; DOG; DRUG EFFECT; DRUG MECHANISM; HEART DEPOLARIZATION; HEART ELECTROPHYSIOLOGY; HEART MUSCLE CELL; NONHUMAN; PATCH CLAMP; POTASSIUM CURRENT;

ANALYSIS OF VARIANCE; ANIMALS; ANTI-ARRHYTHMIA AGENTS; CALCIUM CHANNELS; DOGS; ELECTROPHYSIOLOGY; HEART; HUMANS; PATCH-CLAMP TECHNIQUES; POTASSIUM CHANNELS; PYRIDAZINES;

EID: 0035001691     PISSN: 00281298     EISSN: None     Source Type: Journal    
DOI: 10.1007/s002100100409     Document Type: Article

References (16)

1. Bányász T, Magyar J, Varró A, Kovács A, Gyönös I, Szénási G, Nánási PP (1999) EGIS-7229, the new combined class III antiarrhythmic agent. Lack of EAD inducing effect. Gen Pharmacol 32:329-333
2. + current, on repolarization in human and guinea pig ventricular myocytes. Cardiovasc Res 38:441-450
3. sK channels by the chromanol 293B. Pflugers Arch 432:1094-1096
4. Gyönös I, Kovács A, Pankucsi C, Nánási PP, Szénási G (1997) Electrophysiological effects of EGIS-7229 and its protection against reperfusion-induced arrhythmias in rats. Naunyn-Schmiedeberg's Arch Pharmacol 354(S1):R10
5. Kovács A, Gyönös I, Wellmann J, Nánási PP, Pankucsi C, Szénási G (1996) Pharmacological effects of EGIS-7229, a new antiarrhythmic compound with combined mode of action. J Mol Cell Cardiol 28:A59
6. Nánási PP, Szénási G (1997) EGIS-7229: a new potent antiarrhythmic candidate with combined mode of action. Cardiovasc Drug Rev 15:314-334
7. Pankucsi C, Bányász T, Magyar J, Gyönös I, Kovács A, Varró A, Szénási G, Nánási PP (1997a) Electrophysiological effects of EGIS-7229, a new antiarrhythmic agent, in isolated mammalian and human cardiac tissues. Naunyn-Schmiedeberg's Arch Pharmacol 355:398-405
8. Pankucsi C, Bányász T, Magyar J, Gyönös I, Kovács A, Szénási G, Varró A, Nánási PP (1997b) Electrophysiological effects of EGIS-7229, a new antiarrhythmic agent, in isolated guinea pig papillary muscle. Gen Pharmacol 29:275-280
9. Pankucsi C, Magyar J, Bányász T, Mátyus P, Nánási PP (1998) Novel antiarrhythmic agents with combined mode of action. Drugs 1:554-560
10. Priebe L, Beuckelmann DJ (1998) Simulation study of cellular electric properties in heart failure. Circ Res 82:1206-1223
11. Protiva M (1993) Meeting report of the XIVth International Congress of Heterocyclic Chemistry and XIth Symposium on Chemistry of Heterocyclic Compounds. Drugs Future 18: 1143-1150
12. Szénási G, Pankucsi C, Kovács A, Gyönös I, Bányász T, Magyar J, Szilvássy Z, Nánási PP (1997) Electrophysiological, anti-and proarrhythmic effects of EGIS-7229, a novel antiarrhythmic drug with class III predominance. Eur Heart J 8S:A254
13. The CAST Investigators (1989) Preliminary report: effect of encainide and flecainide on mortality in randomized trial arrhythmia suppression after myocardial infarction. N Engl J Med 321:406-412
14. The CAST II Investigators (1992) Effect of the antiarrhythmic agent moricizine on survival after myocardial infarction. N Engl J Med 327:227-233
15. The SWORD Investigators (1994) Problems for BMS D-sotalol. SCRIP 1973,23
16. Ks in dog ventricular muscle and Purkinje fibre repolarization. J Physiol (Lond) 523:67-81